Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the comparative efficacy and safety of two different doses (75mg day 1 followed
by 150 mg day 2-completion, and 110 mg day 1 followed by 220 mg day 2-completion) of
dabigatran administered orally (capsules), compared to enoxaparin 30 mg twice a day
subcutaneous, in prevention of venous thromboembolism in patients with primary elective total
knee replacement surgery